胰岛素阿仑膦酸钠治疗老年糖尿病骨病患者骨密度及骨转换指标研究.docVIP

胰岛素阿仑膦酸钠治疗老年糖尿病骨病患者骨密度及骨转换指标研究 　　[摘要] 目的 研究胰岛素、阿仑膦酸钠治疗老年糖尿病骨病患者骨密度及骨转换指标的变化。方法 选取该院于2015年6月―2017年2月所收治的80例糖尿病骨病患者作为研究对象，随机分成对照组和观察组，每组40例，对照组给予阿仑膦酸钠联合磺脲类药物治疗，观察组给予阿仑膦酸钠联合胰岛素治疗，观察同一部位在治疗前后的骨密度，对比两组骨密度及股转换指标。结果 观察组骨密度强化度明显高于对照组，对比差异有统计学意义（P0.05）。结论 胰岛素、阿仑膦酸钠治疗老年糖尿病骨病患者骨密度效果显著，值得临床推广应用。 　　[关键词] 胰岛素；阿仑磷酸钠；老年糖尿病；骨密度；骨转化指标 　　[中图分类号] R587.1 [文献标识码] A [文章编号] 1672-4062（2017）06（a）-0083-02 　　[Abstract] Objective This paper tries to study the clinical effect of insulin and alendronate sodium in the bone mineral density and bone turnover markers in elderly diabetes mellitus patients complicated with osteopathy. Methods 80 elderly diabetes mellitus patients complicated with osteopathy treated from June 2015 to February 2017 in this hospital were selected. The subjects were randomly divided into two groups， with 40 cases each group. The control group was given the combined therapy of alendronate sodium and sulfonylurea drug. The observation group was given the combined therapy of alendronate sodium and insulin. The bone mineral density and bone turnover markers of the same position for two groups were observed. Results The intensified bone mineral density for the observation group was significantly higher than that of the control group（P0.05）. Conclusion The combined therapy of insulin and alendronate sodium has an obvious effect in elderly diabetes mellitus patients complicated with osteopathy. It is worthy of clinical promotion and application. 　　[Key words] Insulin； Alendronate sodium； Diabetes mellitus； Bone mineral density； Bone turnover markers 　　2型糖尿病是常?的代谢性疾病，发病率较高，常伴发骨密度减低症状[1]。部分糖尿病患者会被诊断为骨质疏松，占30%左右，导致患者出现周身骨痛、病理性骨折等慢性并发症，不仅给糖尿病患者的身体造成损害，也给患者心理带来深重负担。该组研究选取该院2015年6月―2017年2月收治的80例糖尿病患者作为研究对象，对阿仑膦酸钠联合胰岛素治疗治疗老年糖尿病骨病，对患者骨密度和骨转换指标进行动态观察研究，现报道如下。 　　1 资料与方法 　　1.1 一般资料 　　选取该院收治的80例糖尿病骨病患者作为研究对象，随机分成对照组和观察，每组40例，患者均患者糖尿病并伴发骨质疏松，符合临床诊断标准；对照组中男性26例，女性14例，年龄36～69岁，平均年龄（52.9±13.2）岁；观察组中男性24例，女性16例，年龄34～70岁，平均年龄（54.1±15.2）岁；该组研究排除由其他原因导致的骨质疏松患者；排除6个月内服用增强骨密度药物患者，排除长期卧床患者；排除